Business Wire
12 Oct 2026, 10:30 UTC · 1h ago
Impact · against what's priced in
Teleflex has hit a procedural milestone by completing enrollment for the BIOMAG™-LL study. While this brings the company closer to expanded labeling for longer resorbable magnesium scaffolds, it is a milestone update rather than a clinical result.
No priced-in read yet
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
Teleflex announced the completion of patient enrollment in the BIOMAG™-LL Clinical Study for Freesolve™ Resorbable Magnesium Scaffold in 35 mm and 40 mm lengths.
Newpress release dated 2026-10-12
So whatSuccessful enrollment moves the product closer to potential FDA clearance or expanded labeling for lesions up to 38 mm.
More positive than 66% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Completing patient enrollment for the 35 mm and 40 mm Freesolve™ scaffold lengths moves the product closer to potential FDA clearance for lesions up to 38 mm.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 77% of ticker scores this week
The company successfully completed patient enrollment in a clinical study for its Freesolve Resorbable Magnesium Scaffold.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
43m ago
—
TFX hasn't traded since this ran. Last close $125.12 (Oct 9); the reaction starts at the next open.
TFX chart →
